Literature DB >> 8381817

Oxyrase, a method which avoids CO2 in the incubation atmosphere for anaerobic susceptibility testing of antibiotics affected by CO2.

S K Spangler1, P C Appelbaum.   

Abstract

The Oxyrase agar dilution method, with exclusion of CO2 from the environment, was compared with the reference agar dilution method recommended by the National Committee for Clinical Laboratory Standards (anaerobic chamber with 10% CO2) to test the susceptibility of 51 gram-negative and 43 gram-positive anaerobes to azithromycin and erythromycin. With the Oxyrase method, anaerobiosis was achieved by incorporation of the O2-binding enzyme Oxyrase in addition to susceptibility test medium, antibiotic, and enzyme substrates into the upper level of a biplate. Plates were covered with a Brewer lid and incubated in ambient air. With azithromycin, Oxyrase yielded an MIC for 50% of strains tested (MIC50) and MIC90 of 2.0 and 8.0 micrograms/ml, compared to 8.0 and > 32.0 micrograms/ml in standard anaerobic conditions. At a breakpoint of 8.0 micrograms/ml, 90.4% of strains were susceptible to azithromycin with Oxyrase, compared to 53.2% in the chamber. The corresponding erythromycin MIC50 and MIC90 were 1.0 and 8.0 micrograms/ml with Oxyrase, compared to 4.0 and > 32.0 micrograms/ml by the reference method, with 89.3% of strains susceptible at a breakpoint of 4 micrograms/ml with Oxyrase, compared to 60.6% in CO2. Exclusion of CO2 from the anaerobic atmosphere when testing for susceptibility to azalides and macrolides yielded lower MICs, which may lead to a reconsideration of the role played by these compounds in treatment of infections caused by these strains.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8381817      PMCID: PMC262790          DOI: 10.1128/jcm.31.2.460-462.1993

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  9 in total

1.  In-vitro potency of azithromycin against gram-negative bacilli is method-dependent.

Authors:  A L Barry; P C Fuchs
Journal:  J Antimicrob Chemother       Date:  1991-10       Impact factor: 5.790

2.  Effects of environmental factors on the in vitro potency of azithromycin.

Authors:  J A Retsema; L A Brennan; A E Girard
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

3.  Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms.

Authors:  J Retsema; A Girard; W Schelkly; M Manousos; M Anderson; G Bright; R Borovoy; L Brennan; R Mason
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

4.  Correlation of the extravascular pharmacokinetics of azithromycin with in-vivo efficacy in models of localized infection.

Authors:  A E Girard; D Girard; J A Retsema
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

5.  In-vitro activity of azithromycin against various Gram-negative bacilli and anaerobic bacteria.

Authors:  M D Kitzis; F W Goldstein; M Miégi; J F Acar
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

6.  The pharmacokinetics of azithromycin in human serum and tissues.

Authors:  G Foulds; R M Shepard; R B Johnson
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

Review 7.  Tissue-directed pharmacokinetics.

Authors:  J J Schentag; C H Ballow
Journal:  Am J Med       Date:  1991-09-12       Impact factor: 4.965

8.  Effect of carbon dioxide and pH on susceptibility of Bacteroides fragilis group to erythromycin.

Authors:  S L Hansen; P Swomley; G Drusano
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

9.  Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution.

Authors:  A E Girard; D Girard; A R English; T D Gootz; C R Cimochowski; J A Faiella; S L Haskell; J A Retsema
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

  9 in total
  7 in total

1.  Effect of medium age and supplementation with the biocatalytic oxygen-reducing reagent oxyrase on in vitro activities of tigecycline against recent clinical isolates.

Authors:  Peter J Petersen; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

2.  Comparative antianaerobic activities of the ketolides HMR 3647 (RU 66647) and HMR 3004 (RU 64004).

Authors:  L M Ednie; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

3.  Antianaerobic activity of the ketolide RU 64004 compared to activities of four macrolides, five beta-lactams, clindamycin, and metronidazole.

Authors:  L M Ednie; S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

4.  Susceptibilities of 201 anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin by oxyrase agar dilution and E test methodologies.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

5.  Activity of telithromycin (HMR 3647) against anaerobic bacteria compared to those of eight other agents by time-kill methodology.

Authors:  K L Credito; L M Ednie; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

6.  Effect of CO2 on susceptibilities of anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

7.  The common prophylactic therapy for bowel surgery is ineffective for clearing Bacteroidetes, the primary inducers of systemic inflammation, and causes faster death in response to intestinal barrier damage in mice.

Authors:  Daniel Sinsimer; Amira Esseghir; May Tang; Amale Laouar
Journal:  BMJ Open Gastroenterol       Date:  2015-02-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.